CONMED Form 3: Kim Kelderman Named Director; No Shares Reported

Rhea-AI Filing Summary

CONMED Corporation filed a Form 3 reporting that Kim Kelderman became a director on 09/08/2025. The filing shows 0 shares of common stock beneficially owned as of the event date and lists the reporting relationship as Director. The Form 3 was executed by power of attorney on 09/09/2025. This is an initial Section 16 filing required when an insider becomes a director; it discloses current ownership (none reported) and does not list any derivative holdings or other indirect ownership.

Positive

• Director appointment disclosed on 09/08/2025, satisfying Section 16 reporting rules
• Transparent initial filing showing current ownership position (reported as 0 shares)

Negative

• No shares reported by the new director, so there is no immediate equity alignment disclosed

Insights

Corporate Governance Analyst

Initial director filing shows appointment with no current stock ownership.

The Form 3 confirms Kim Kelderman assumed a board seat at CONMED on 09/08/2025 and reported 0 shares of common stock. This filing fulfills Section 16 reporting obligations for insiders.

Because no equity or derivative holdings are disclosed, there is no immediate change to shareholding structure; any future purchases or granted awards would require additional filings. The filing was signed by a power of attorney on 09/09/2025.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kelderman Kim

Role Director

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 0 shares (Direct)

Footnotes (1)

1. F1. Remarks: Kim Kelderman became a Director of CONMED on September 8, 2025

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Accepted by SEC EDGAR 09/09/2025 - 01:12 PM Learn about SEC filing dates

FAQ

What does CONMED's Form 3 for Kim Kelderman disclose?

The Form 3 discloses that Kim Kelderman became a director on 09/08/2025 and reported 0 shares of common stock.

Does the Form 3 show any stock options or derivative holdings for Kim Kelderman (CNMD)?

No. Table II in the filing lists no derivative securities and the Form 3 reports only common stock with 0 shares owned.

Who signed the Form 3 for Kim Kelderman and when?

The Form 3 was signed by Thomas Fistek on behalf of Kim Kelderman by power of attorney on 09/09/2025.

Is this filing an initial report or an amendment for CNMD?

This is an initial Form 3 filing reporting the director appointment; the form indicates it was filed by one reporting person.

Will future equity purchases by Kim Kelderman be reported?

Yes. Any future acquisitions, dispositions, or grants by the director would require subsequent Section 16 filings (Forms 4 or 5) as applicable.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Kelderman Kim

(Last) (First) (Middle)

C/O CONMED CORPORATION

11311 CONCEPT BOULEVARD

(Street)

LARGO FL 33773

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/08/2025

3. Issuer Name and Ticker or Trading Symbol
CONMED Corp [ CNMD ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	0	D(1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Remarks: Kim Kelderman became a Director of CONMED on September 8, 2025

	/s/ Thomas Fistek for Kim Kelderman by Power of Attorney	09/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.